Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

NCT02482311 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer, TNBC, SCLC, Other Solid Tumours

Interventions

DRUG: AZD 1775

Sponsor

AstraZeneca